Chicago, Jan. 20, 2023 (GLOBE NEWSWIRE) -- According to the new market research report "Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC, Rx) Application (Diabetes, Oncology, CVD) - Global Forecast to 2027", The global Active Pharmaceutical Ingredient market is estimated to reach USD 216.4 billion by 2027 from USD 145.9 billion in 2022, at a CAGR of 8.2% during the forecast period.
Browse in-depth TOC on "Active Pharmaceutical Ingredient Market"
397 - Tables
48 - Figures
377 - Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263
Scope of the Report:
| Report Coverage | Details |
| Market Size | USD 216.4 billion by 2027 |
| CAGR | 8.2% |
| Historical Data | 2020-2027 |
| Base Year | 2021 |
| Forecast Period | 2022-2027 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Potency, Type of Synthesis, Type of Drug, Therapeutic Application and Region |
| Geographies Covered | North America (US, Canada), Europe (Germany, UK, France, and Rest of Europe), Asia Pacific (Japan, China, India, South Korea, and Rest of Asia Pacific), and the Rest of the World |
| Key Companies Profiled/Vendors | Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Cipla, Inc. (India), Mylan N.V. (US), Dr. Reddy’s Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), API Pharma Tech (India), BDR Pharmaceuticals Internationals Pvt. Ltd. (India), Sreepathi Pharmaceuticals Limited (India), Shilpa Medicare Limited (India), Evonik Industries AG (Germany), and Aurobindo Pharma Limited (India). |
| Key Market Opportunities | Emerging biosimilars market |
| Key Market Drivers | Focus on precision medicine |
Factors such as an increased incidence of chronic diseases, the growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. However, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=263
On the basis of type, the APIs (Active Pharmaceutical Ingredient) market is segmented into innovative APIs and generic APIs. The innovative APIs segment is expected to dominate this market in 2021. Factors such as the higher price of innovative APIs as compared to their generic equivalents are driving the market. However, the generic APIs segment is expected to grow at a higher CAGR during the forecast period owing to the gradual shift in prescriptions from branded drugs to generic drugs across the globe.
On the basis of the type of synthesis, the Active Pharmaceutical Ingredient (APIs) market is segmented into synthetic APIs and biotech APIs. Synthetic APIs are expected to command a larger share of the market in 2021. Factors such as the increasing emergence of new molecules in the market and an increased number of new product approvals are driving the market.
On the basis of therapeutic applications, the APIs market is segmented into communicable diseases, oncology, cardiovascular diseases, diabetes, pain management, respiratory diseases, and other therapeutic applications (CNS and neurological disorders, nephrology, endocrinology, orthopedics, ophthalmology, and gastrointestinal disorders). The communicable diseases segment is the largest segment of the global APIs market. Factors such as the increasing global incidence of communicable diseases and growing antimicrobial resistance are driving market growth.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=263
Geographical Growth Scenario:
On the basis of region, the active pharmaceutical ingredients market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2021, North America dominated the market, followed by Europe. The market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as the growing prevalence of chronic diseases, increase in disposable income, and initiatives taken by the government to encourage the adoption of generics to drive the APIs market in this region.
Key Players:
The key players in the market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK).
Browse Adjacent Markets: Pharmaceuticals Market Research Reports & Consulting
Browse Related Reports:
Pharmaceutical Excipients Market
Oligonucleotide Synthesis Market
miRNA Sequencing and Assay Market
